Clinical Trial Update: An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy [Phase 1]

View source ↗

Summary

Phase 1 exploratory trial evaluating changes in synovial immune responses after BMS-188667 therapy in active rheumatoid arthritis patients on background DMARDs …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• BMS-188667

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED